CJC-1295
Last reviewed 2026-10-30
Our read Opinion
The December 2024 FDA advisory committee opposed listing CJC-1295-related substances for compounding. WADA 2026 S2.2.4 prohibits CJC-1295.
- Type
- Research-only / unapproved
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Not cleared (advisory panel rejected)
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to increase natural growth hormone release
- —Claimed to support fat loss, lean muscle, sleep quality and recovery
Long-acting growth-hormone-releasing hormone analogue; the DAC form binds albumin to prolong exposure and raise GH and IGF-1. Products called non-DAC CJC-1295 are not equivalent to the studied long-acting form.
Not FDA-approved. Early healthy-volunteer trials demonstrated hormone changes, not approved treatment benefits; FDA reports serious adverse events and limited clinical data.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
Changes in GH and IGF-1 are surrogate findings, not evidence of healthier aging. Product-name ambiguity further weakens comparisons with published trials.
No news yet for this peptide.
Bigger natural growth-hormone pulses for fat loss, lean muscle, sleep quality and recovery.
Lose fat on a GLP-1 while holding on to muscle.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.